New analyses show Novartis' EntrestoTM reduced cardiovascular death or hospitalization forheart failure, consistently benefitting patients with reduced ejection fractionregardless of prior heart failure hospital admissions or background therapy | Novartis
Entresto 24/26 | healthdirect
ENTRESTOâ„¢ (sacubitril/valsartan) for the Management of Heart Failure